X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK LTD TORRENT PHARMA/
MERCK LTD
 
P/E (TTM) x 41.4 44.7 92.5% View Chart
P/BV x 5.8 5.9 98.3% View Chart
Dividend Yield % 0.9 0.6 153.6%  

Financials

 TORRENT PHARMA   MERCK LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
MERCK LTD
Dec-17
TORRENT PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,5501,358 114.2%   
Low Rs1,144933 122.6%   
Sales per share (Unadj.) Rs354.7665.0 53.3%  
Earnings per share (Unadj.) Rs40.156.6 70.8%  
Cash flow per share (Unadj.) Rs64.272.5 88.6%  
Dividends per share (Unadj.) Rs14.0015.00 93.3%  
Dividend yield (eoy) %1.01.3 79.4%  
Book value per share (Unadj.) Rs273.1441.7 61.8%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.7 220.5%   
Avg P/E ratio x33.620.2 166.0%  
P/CF ratio (eoy) x21.015.8 132.7%  
Price / Book Value ratio x4.92.6 190.2%  
Dividend payout %34.926.5 131.8%   
Avg Mkt Cap Rs m227,89719,011 1,198.8%   
No. of employees `00014.71.5 952.1%   
Total wages/salary Rs m11,3531,696 669.2%   
Avg. sales/employee Rs Th4,083.07,150.0 57.1%   
Avg. wages/employee Rs Th772.31,098.7 70.3%   
Avg. net profit/employee Rs Th461.3608.2 75.8%   
INCOME DATA
Net Sales Rs m60,02111,040 543.7%  
Other income Rs m2,988240 1,246.7%   
Total revenues Rs m63,00911,279 558.6%   
Gross profit Rs m13,4931,376 980.4%  
Depreciation Rs m4,086264 1,547.7%   
Interest Rs m3,0850-   
Profit before tax Rs m9,3101,352 688.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m2,529583 433.9%   
Profit after tax Rs m6,781939 722.1%  
Gross profit margin %22.512.5 180.3%  
Effective tax rate %27.243.1 63.0%   
Net profit margin %11.38.5 132.8%  
BALANCE SHEET DATA
Current assets Rs m52,6237,523 699.5%   
Current liabilities Rs m52,0222,253 2,309.4%   
Net working cap to sales %1.047.7 2.1%  
Current ratio x1.03.3 30.3%  
Inventory Days Days12052 229.3%  
Debtors Days Days7641 188.0%  
Net fixed assets Rs m85,0161,240 6,857.8%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m45,3767,167 633.2%   
Net worth Rs m46,2227,333 630.4%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4329,912 1,436.9%  
Interest coverage x4.0NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.1 37.8%   
Return on assets %6.99.5 73.1%  
Return on equity %14.712.8 114.6%  
Return on capital %14.220.8 68.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5801,015 1,437.0%   
Fx outflow Rs m3,6003,043 118.3%   
Net fx Rs m10,980-2,028 -541.4%   
CASH FLOW
From Operations Rs m8,942537 1,666.4%  
From Investments Rs m-47,070-476 9,882.3%  
From Financial Activity Rs m34,174-220 -15,547.7%  
Net Cashflow Rs m-3,655-160 2,291.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 280 Points Lower; IT and Healthcare Stocks Witness Selling(Closing)

After trading on a negative note throughout the day, share markets in India continued their downtrend during the closing hours and ended the day in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

You Can Buy Select Auto Stocks Now for Big Long-Term Returns(The 5 Minute Wrapup)

Oct 17, 2018

Irrespective of the earnings hiccups, these businesses be setting new profit records.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Stop! Read This Before You Cancel Your SIPs(Profit Hunter)

Oct 11, 2018

Read this before you stop your SIP's in equity mutual funds.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

Why Oil Cannot Be Sold to India in Rupees(Vivek Kaul's Diary)

Oct 16, 2018

Oil is bought and sold internationally in terms of dollars. And any change to this, will be attacking the exorbitant privilege of the US dollar.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Oct 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - PFIZER COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS